NASDAQ:JNCEJounce Therapeutics Stock Price, Forecast & News

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JNCE shares have increased by 32.7% and is now trading at $5.68. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jounce Therapeutics.

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Jounce Therapeutics.

Jounce Therapeutics Inc (NASDAQ:JNCE) released its earnings results on Wednesday, May, 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.21. Jounce Therapeutics had a net margin of 46.11% and a return on equity of 28.10%. View Jounce Therapeutics' earnings history.

4 brokers have issued twelve-month price targets for Jounce Therapeutics' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Jounce Therapeutics' share price to reach $9.50 in the next year. This suggests a possible upside of 67.3% from the stock's current price. View analysts' price targets for Jounce Therapeutics.

News coverage about JNCE stock has been trending very negative recently, InfoTrie reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Jounce Therapeutics earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View the latest news aboutJounce Therapeutics.

Jounce Therapeutics saw a decrease in short interest in April. As of April 30th, there was short interest totaling 2,000,000 shares, a decrease of 11.9% from the April 15th total of 2,270,000 shares. Based on an average daily volume of 378,700 shares, the short-interest ratio is currently 5.3 days. Approximately 12.3% of the shares of the stock are sold short. View Jounce Therapeutics' Current Options Chain.

Some companies that are related to Jounce Therapeutics include Avrobio (AVRO), Aerie Pharmaceuticals (AERI), Adaptimmune Therapeutics (ADAP), Atara Biotherapeutics (ATRA), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), AVITA MED LTD/S (RCEL), Vericel (VCEL), Harpoon Therapeutics (HARP), Oyster Point Pharma (OYST), Scholar Rock (SRRK), MeiraGTx (MGTX), Prevail Therapeutics (PRVL), Aptose Biosciences (APTO) and Innate Pharma (IPHYF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), Crispr Therapeutics (CRSP), Progenics Pharmaceuticals (PGNX), Bausch Health Companies (BHC), Exelixis (EXEL), Incyte (INCY), Nektar Therapeutics (NKTR), Omeros (OMER), Sangamo Therapeutics (SGMO) and AT&T (T).

(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.65%), Acadian Asset Management LLC (2.81%), AQR Capital Management LLC (1.83%), State Street Corp (1.23%), Massachusetts Financial Services Co. MA (0.83%) and Granahan Investment Management Inc. MA (0.78%). Company insiders that own Jounce Therapeutics stock include Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View institutional ownership trends for Jounce Therapeutics.

JNCE stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Deutsche Bank AG, JPMorgan Chase & Co., Geode Capital Management LLC, Bank of New York Mellon Corp, Systematic Financial Management LP, UBS Group AG, and Morgan Stanley. Company insiders that have sold Jounce Therapeutics company stock in the last year include Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, and Richard /Ca/ Murray. View insider buying and selling activity for Jounce Therapeutics.

JNCE stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Massachusetts Financial Services Co. MA, Acadian Asset Management LLC, Russell Investments Group Ltd., Granahan Investment Management Inc. MA, Congress Asset Management Co. MA, Los Angeles Capital Management & Equity Research Inc., and GSA Capital Partners LLP. View insider buying and selling activity for Jounce Therapeutics.

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of JNCE stock can currently be purchased for approximately $5.68.

Jounce Therapeutics has a market capitalization of $193.40 million and generates $147.87 million in revenue each year. The company earns $56.82 million in net income (profit) each year or $1.66 on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.

The official website for Jounce Therapeutics is www.jouncetx.com.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.